Personalis
Personalis Nabs $50M Investment From Merck, Extends Collaboration with Moderna
The company extended its collaboration to further advance an investigational personalized vaccine therapy under development by Merck and Moderna.
Personalis, Tempus Expand MRD Diagnostics Partnership to Include Biopharma
Tempus will now offer Personalis' NeXT Personal Dx minimal residual disease assay to pharmaceutical and biotech customers.
Myriad Genetics, Personalis Cross-License MRD Technology
The companies inked an agreement to co-license their minimal residual disease technology in an effort to broaden testing access and boost adoption.
As ctDNA testing for early-stage tumors gains traction, clinicians eagerly await more clarity on overall utility and the potential value of increased sensitivity.
Personalis, Tempus Partner to Commercialize Blood-Based Minimal Residual Disease Test
Tempus will market Personalis' NeXT Personal Dx liquid biopsy assay while Personalis completes its clinical validation in more indications.